Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2009-7-31
pubmed:abstractText
Increased expression of the astrocytic intermediate filament protein glial fibrillary acidic protein (GFAP) is a characteristic of astrogliosis. This process occurs in the brain during aging and neurodegeneration and coincides with impairment of the ubiquitin proteasome system. Inhibition of the proteasome impairs protein degradation; therefore, we hypothesized that the increase in GFAP may be the result of impaired proteasomal activity in astrocytes. We investigated the effect of proteasome inhibitors on GFAP expression and other intermediate filament proteins in human astrocytoma cells and in a rat brain model for astrogliosis. Extensive quantitative RT-PCR, immunocytochemistry, and Western blot analysis resulted unexpectedly in a strong decrease of GFAP mRNA to <4% of control levels [Control (DMSO) 100+/-19.2%; proteasome inhibitor (epoxomicin) 3.5+/-1.3%, n=8; P < or = 0.001] and a loss of GFAP protein in astrocytes in vitro. We show that the proteasome alters GFAP promoter activity, possibly mediated by transcription factors as demonstrated by a GFAP promoter-luciferase assay and RT(2) Profiler PCR array for human transcription factors. Most important, we demonstrate that proteasome inhibitors also reduce GFAP and vimentin expression in a rat model for induced astrogliosis in vivo. Therefore, proteasome inhibitors could serve as a potential therapy to modulate astrogliosis associated with CNS injuries and disease.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Aug
pubmed:issn
1530-6860
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
23
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
2710-26
pubmed:dateRevised
2010-12-3
pubmed:meshHeading
pubmed-meshheading:19332645-Animals, pubmed-meshheading:19332645-Astrocytes, pubmed-meshheading:19332645-Brain, pubmed-meshheading:19332645-Cell Line, pubmed-meshheading:19332645-Cell Survival, pubmed-meshheading:19332645-Down-Regulation, pubmed-meshheading:19332645-Glial Fibrillary Acidic Protein, pubmed-meshheading:19332645-HeLa Cells, pubmed-meshheading:19332645-Humans, pubmed-meshheading:19332645-Intermediate Filament Proteins, pubmed-meshheading:19332645-Intermediate Filaments, pubmed-meshheading:19332645-Male, pubmed-meshheading:19332645-Nerve Tissue Proteins, pubmed-meshheading:19332645-Oligopeptides, pubmed-meshheading:19332645-Protease Inhibitors, pubmed-meshheading:19332645-Proteasome Endopeptidase Complex, pubmed-meshheading:19332645-RNA, Messenger, pubmed-meshheading:19332645-Rats, pubmed-meshheading:19332645-Rats, Wistar, pubmed-meshheading:19332645-Stress, Physiological, pubmed-meshheading:19332645-Transcription, Genetic, pubmed-meshheading:19332645-Transcription Factors, pubmed-meshheading:19332645-Vimentin
pubmed:year
2009
pubmed:articleTitle
Intermediate filament transcription in astrocytes is repressed by proteasome inhibition.
pubmed:affiliation
Department of Astrocyte Biology and Neurodegeneration, Netherlands Institute for Neuroscience, Royal Netherlands Academy of Arts and Sciences, Amsterdam, The Netherlands.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't